ABSTRACT

Diabetes Mellitus is a chronic metabolic disorder characterized by chronic hyperglycemia caused by insulin deficiency, often combined with insulin resistance and it is the most common endrocrine disorder affecting 3 – 4 % of the population and its incidence is rising day by day. In the year 2000, 150 million people worldwide had diabetes and expected to increase year by year. By 2030 the WHO estimates that number of people with diabetes will almost reach to double. For more than two decades, researchers have attempted to find a way to use the skin as a portal of entry for drugs in order to overcome problems associated with conventional modes of drug administration. The principle of transdermal drug delivery systems is to deliver drug across epidermis to achieve systemic effect over a prolonged period of time. Because of these attributes, transdermal drug delivery systems offer many advantages over conventional drug delivery system such as reduced side effects, improved patient compliance, elimination of first-pass metabolism, and sustained drug delivery. Considering all these problems associated with oral administration of anti diabetic drug, attempt has been made to develop TDDS in order to achieve a better release pattern. Therefore, the present study involves the development of an anti diabetic drug (metformin hydrochloride) in transdermal drug delivery form and their evaluation. Keywords: diabetes mellitus, skin, antidiabetic drug, TDDS
Publication date: 01/06/21

https://ijbpas.com/pdf/2021/June/MS_IJBPAS_2021_5505.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.6.5505